An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy
- 23 August 2022
- journal article
- review article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 366, 110108
Abstract
No abstract availableKeywords
Funding Information
- Deanship of Scientific Research, University of Jordan (DSR-2021-01-03102)
- Jouf University
This publication has 68 references indexed in Scilit:
- HER2: An emerging target in colorectal cancerCurrent Problems in Cancer, 2018
- Metastatic and triple-negative breast cancer: challenges and treatment optionsDrug Delivery and Translational Research, 2018
- Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancerCancer Treatment Reviews, 2018
- HER2-positive breast cancer: Current and new therapeutic strategiesThe Breast, 2018
- EGFR-TKIs in Non-Small-Cell Lung Cancer: Focus on Clinical Pharmacology and Mechanisms of ResistancePharmacogenomics, 2018
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal CancerCancer Discovery, 2018
- Treatment of EGFR T790M-Positive Non-Small Cell Lung CancerTargeted Oncology, 2018
- Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapiesOncogene, 2018
- The role of pazopanib on tumour angiogenesis and in the management of cancers: A reviewBiomedicine & Pharmacotherapy, 2017
- EGFR heterogeneity and implications for therapeutic intervention in glioblastomaNeuro-Oncology, 2017